Immunome Inc.
Company Stats
- Market Cap
- $2.4B
- as of Sep 30, 2026
- Shares Outstanding
- 113.6M
- Free Float
- 83.1%
Income Statement
- Revenue
- $6.9M
- Operating Income
- -$224.1M
- Net Income
- -$212.4M
- EBITDA
- -$221.6M
- FCF Margin, 3Y Avg
- -1418.3%
- FCF Margin, Worst Year
- -2890.1%
Cash Flow
- Free Cash Flow
- -$200.6M
- FCF Yield
- -8.2%
- Owner FCF Yield
- -9.3%
Balance Sheet
- Cash & Equivalents
- $653.5M
Returns & Capital
- SBC, 3Y Avg
- $15.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $6.9M | -$200.6M | -2890.1% |
| FY2024 | $9.0M | -$118.0M | -1304.8% |
| FY2023 | $14.0M | -$8.4M | -59.9% |
| FY2022 | — | -$28.9M | — |
| FY2021 | — | -$18.3M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 12, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges